Tracells
Diagnosis of Inflammatory Bowel Diseases
Startup Pre-Seed Health Tech & Life Sciences Est. 2024
Total Raised
$1M
Pre-Seed
Last Round
Undisclosed
2 rounds
Investors
1
1 public
Team
2
1-10 employees
Confidence
80/100
News
1
articles
About
Tracells specializes in non-invasive diagnostic testing for inflammatory bowel diseases (IBD) using advanced RNA transcriptomics and AI-driven classifiers. Their stool tests utilize RNA profiles from intestinal cells to accurately diagnose IBD, assess inflammation severity and location, and predict therapy response. This method aims to replace invasive procedures like endoscopies with a convenient, home-based testing alternative, offering precise, cost-effective monitoring and disease management.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Core Technology
BiologicalsCells
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
pharmaceuticalsnon-invasivediagnosticsinflammatory-diseases
Funding & Events
Apr 2024
Pre-Seed $1M
G.O Innovation
Apr 2024
Non-equity Undisclosed
Israel Innovation Authority
News (1)
Mar 8, 2024 · kalkinemedia.com
Not applicable
Tracells Emerges as a Pioneer in Gastrointestinal Diagnostics and Therapeutics
Not applicable
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
7
District
North District
Founded
2024
Registrar
516912649
Locations
Yokne'am Illit, Israel
Links
Website
LinkedIn
Admin
Last Update
May 27, 2024
Verified by
Yanina Wainscheinker
Missing
sector, video or image, markets, not claimed
Team (2)
Maya Hanum
Co-Founder & CEO
Founder
Yotam Harnik
Co-Founder & CTO
Founder
Internal
Created by
Maor Perlov (maor.perlov@sncentral.org)
Created
2024-05-21T00:00:00.000Z